Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Evolving role of HER2 targeted therapies in gastroesophageal cancers

Barbara Burtness • 28 May 2020
ASCO 2020
Gastrointestinal Cancer Trastuzumab

Barbara Burtness, MD, of Yale Cancer Center, New Haven, CT, discusses advancements in targeting HER2 for the treatment of gastroesophageal cancers. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Barbara Burtness

0:47
Novel KRAS-targeting agents on the horizon
Barbara Burtness • 7 Aug 2022
0:35
Data on KRAS inhibitors in lung cancer at WCLC 2022
Barbara Burtness • 7 Aug 2022
4:11
CDKN2A and TP53 mutation in HPV-negative HNSCC
Barbara Burtness • 28 May 2020
7:56
KEYNOTE-048: progression post next line for R/M HNSCC
Barbara Burtness • 28 May 2020

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals